Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M.

J Invest Dermatol. 2006 Mar;126(3):575-83.

2.
3.

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).

Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A.

Clin Lymphoma. 2002 Mar;2(4):222-8.

PMID:
11970761
4.

Denileukin diftitox.

Figgitt DP, Lamb HM, Goa KL.

Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. Review.

PMID:
11702307
5.

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A.

J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8.

PMID:
20212249
6.
7.
8.

Denileukin diftitox.

Saxon M.

Clin J Oncol Nurs. 2000 Nov-Dec;4(6):289, 293.

PMID:
11899329
9.
10.

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.

Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L.

J Clin Oncol. 2004 Oct 15;22(20):4095-102. Epub 2004 Sep 7.

PMID:
15353540
11.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J.

J Clin Oncol. 2001 Jan 15;19(2):376-88.

PMID:
11208829
12.

Clinical experience with denileukin diftitox (ONTAK).

Foss F.

Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. Review.

PMID:
16516670
13.

Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.

Kadin ME, Vonderheid EC.

Nat Rev Clin Oncol. 2010 Aug;7(8):430-2. doi: 10.1038/nrclinonc.2010.105. No abstract available.

PMID:
20668480
14.
15.

Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.

Talpur R, Duvic M.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):180-5. doi: 10.1016/j.clml.2012.01.011. Epub 2012 Apr 21.

PMID:
22521504
16.

Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.

Duvic M, Geskin L, Prince HM.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377-84. doi: 10.1016/j.clml.2013.02.020. Epub 2013 Jun 14.

PMID:
23770157
17.

Denileukin diftitox as novel targeted therapy for lymphoid malignancies.

Wong BY, Gregory SA, Dang NH.

Cancer Invest. 2007 Sep;25(6):495-501. Review.

PMID:
17882663
18.

Denileukin diftitox for the treatment of panniculitic lymphoma.

McGinnis KS, Shapiro M, Junkins-Hopkins JM, Smith M, Lessin SR, Vittorio CC, Rook AH.

Arch Dermatol. 2002 Jun;138(6):740-2. No abstract available.

PMID:
12056952
19.

Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).

Talpur R, Apisarnthanarax N, Ward S, Duvic M.

Leuk Lymphoma. 2002 Jan;43(1):121-6.

PMID:
11908715
20.

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.

Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L.

Br J Haematol. 2007 Feb;136(3):439-47.

PMID:
17233846

Supplemental Content

Support Center